Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study

Affiliations

• ¹ Department of Haematology and Oncology, Osaka University Graduate School of Medicine C9, Suita, Osaka, Japan.
• ² Department of Haematology, NTT Medical Centre Tokyo, Shinagawa-ku, Tokyo, Japan.
• ³ Genentech, a Member of the Roche Group, South San Francisco, California, USA.
• ⁴ Department of Haematology, Tohoku University Hospital, Aoba-ku, Sendai, Japan.
• ⁵ F. Hoffmann-La Roche, Ltd, Basel, Switzerland.
• ⁶ Department of Haematology and Bone Marrow Transplant Department, CHU Paris GH St Louis Lariboisière et Fernand-Widal Hospital, Paris, France.
• ⁷ Department of Haematology and Stem Cell Transplantation, West German Cancer Centre, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.